Biomea Fusion, Inc. · NASDAQ:BMEA
Biomea Fusion — Investor Presentation (July 2021)
25 slides from Biomea Fusion's investor presentation, Jul 19, 2021
Slide 1: Corporate Presentation July 2021
Exhibit 99.1 Corporate Presentation July 2021Exhibit 99.1 Corporate Presentation July 2021
Slide 2: Disclaimer and Forward-Looking Statement
Disclaimer and Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risk
Slide 3: Irreversible Drug Discovery & Development Platform
Irreversible Drug Discovery & Our Mission is to revolutionize drug development Development Platform in order to create more effective therapies for patients in need. Three Innovative Programs Announced to date Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery an
Slide 4: Biomea Fusion History
Biomea Fusion History A Discovery Platform in Development since 2017 Biomea and A2A form Lead candidates Initial Public Offering 2018 2020 Biomea Fusion to develop selected for menin (NASDAQ: BMEA) MLL-Fusion and menin Raises $158 M at $17/share reversible menin Program dependent cancers JPMorgan, J
Slide 5: Biomea's Team
Biomea’s Team Diverse team with significant drug development experience Taisei Kinoshita Naomi Cretcher Heow Tan Alex Cacovean MD Thorsten Kirschberg Thomas Butler Ramses Erdtmann Franco Valle Chief of People Chief Technical & Exec. Medical EVP of Chemistry VP of Biology Chairman & CEO President & C
Slide 6: Biomea FUSION System Discovery Platform
Biomea FUSION™ System Discovery Platform We leverage our FUSION™ System to discover and develop novel irreversible inhibitors against targets essential for cancer Scaffold Scaffold Scaffold 2 3 1 Our FUSION™ System Discovery Platform encompasses the following: • Target selection: Expertise in struct
Slide 7: Irreversible Drugs offer several potentially significant Advantages
Irreversible Drugs offer several potentially significant Advantages Greater Therapeutic High Selectivity Deep Target-Inactivation Window • Irreversible inhibitors can cause • Irreversible drugs are designed to • Irreversible drugs leverage both non- permanent inactivation of bound maintain their eff
Slide 8: Irreversible Drugs are designed to uncouple Drug-Effects from Drug-Exposure
Irreversible Drugs are designed to uncouple Drug-Effects from Drug-Exposure • The chart shows Ibrutinib, an approved, irreversible PK/PD – Current Commercial Drug BTK inhibitor. • Irreversible drugs can be designed to achieve nearly complete occupancy in short time, and occupancy is intended to be s
Slide 9: Irreversible Drugs have a long History in Medicine
Biomea Irreversible Drugs have a long History in Medicine Aspirin was the first irreversible drug, discovered in 1899, and is to date the most used medicine in the world Aspirin Sofosbuvir (Sovaldi) Ibrutinib (Imbruvica) Penicillin Tenofovir (Viread) Osimertinib (Tagrisso) 9Biomea Irreversible Drugs
Slide 10: High Barriers to Entry to develop Irreversible Drugs
High Barriers to Entry to develop Irreversible Drugs Complexity Safety and Toxicity The discovery and development of irreversible drugs has been While the irreversible binding modality can provide a high degree limited by: of selectivity, potential risks have presented barriers: • Need for specializ
Slide 11: Biomea's Pipeline of Irreversible Proprietary Assets
Biomea’s Pipeline of Irreversible Proprietary Assets We are building a platform of irreversible inhibitors in multiple tumor types KEY IND- DISCOVERY PHASE 1 PHASE 2 PHASE 3 ANTICIPATED ENABLING MILESTONES File IND in the BMF-219 menin dependent second half of Irreversible Menin cancers 2021 Inhibit
Slide 12: Menin – a Protein important to transcriptional Regulation
Menin – a Protein important to transcriptional Regulation Menin impacts major processes such as cell cycle control, apoptosis, and DNA damage repair Liquid Tumor Role Solid Tumor Role Source: Cierpicki & Grambacka, Future Med. Chem. (2014) Modified after Uckelmann (Scott Armstrong Lab) , ASH 2018, A
Slide 13: Menin-MLL Interaction
Menin-MLL Interaction Schematic of key proteins and their interactions in the regulation of gene transcription • Inhibition of the menin-MLL Transcriptional interaction leads to upregulation reduction in MEN1 Biomea of leukemic drivers: transcription, resulting in HOX genes, MEIS1, down regulation o
Slide 14: BMF-219 has demonstrated rapid Reduction in Menin dependent Gene Expression
BMF-219 has demonstrated rapid Reduction in Menin dependent Gene Expression = Target Engagement • Molecular responses following MEN1 MEIS1 HOXA9 DNMT3A * TPM treatment with BMF-219 in 8 0.8 80 0.20 MOLM-13 cells (an acute myeloid leukemia cell line with a 6 0.6 60 0.15 KMT2A-MLLT3 fusion). 6h 4 0.4
Slide 15: BMF-219 has demonstrated Dose Dependent Cell Differentiation
BMF-219 has demonstrated Dose Dependent Cell Differentiation • Dose dependent elevation of myeloid TPM differentiation marker (ITGAM) at 24 hours irreversible reversible @10µM reversible 0.3 after administration of BMF-219 demonstrated target engagement in MOLM-13 cells. • Comparable exposures of re
Slide 16: BMF-219 demonstrated superior, rapid and durable Responses in Leukemia Cell Lines
BMF-219 has demonstrated superior, rapid and durable Responses in Leukemia Cell Lines MV4;11 MOLM-13 NPM1 mutant 1200000 5000000 4000000 BMF-05 MI-503 1000000 BMF-219 DMSO 4000000 3000000 800000 3000000 600000 2000000 2000000 400000 1000000 1000000 200000 0 0 0 T4 T7 T11 T14 T4 T7 T11 T14 T4 T7 T11
Slide 17: BMF-219 Impaired Cell Survival in Multiple Myeloma and Pancreatic Cancer Models
BMF-219 Impaired Cell Survival in Multiple Myeloma and Pancreatic Cancer Models Multiple Myeloma Cell Viability KRAS Pancreatic Cancer Viability (KMS-20 cells, 0.560µM dose) (MIA-PaCa--2 cells, 0.560µM) 4000000 100000 BMF-5 BMF-219 DMSO BMF-219 MI-503 BMF-05 DMSO 80000 3000000 60000 2000000 40000 10
Slide 18: BMF-219 Inhibited Cell Survival in Multiple Cancer Cell Lines
BMF-219 Inhibited Cell Survival in Multiple Cancer Cell Lines Cell Line/Tumor Type IC50 (µM) MOLM-13/AML 0.05 • Responses to BMF-219 were Fusion MV4;11/ALL-AML 0.07 screened across a range of NPM1 Mutation OCI-AML3/AML 0.14 cancer cell lines. MIA-PaCa-2/Pancreatic 0.23 KRAS NCI-H23/Lung 0.26 • Poten
Slide 19: BMF-219 Inhibited Patient derived AML cells at very low Exposures
BMF-219 Inhibited Patient derived AML cells at very low Exposures vs Reversible Inhibitors Patient 320: NPM1 AML, Treatment Naïve Patient 340: NPM1 AML, Treatment Naïve Patient 350: MLD AML, Relapsed Refractory Patient 400: MLL-r AML, Treatment Naïve 100% 100% Patient 320: NPM1 AML, Treatment Naïve
Slide 20: Selectivity Profiling of BMF-219 in multiple Safety Models
Selectivity Profiling of BMF-219 in multiple Safety Models Kinase screening Glutathione reactivity Mean half-life • In-house analysis of menin revealed limited structural • Drugs with limited non-specific interactions have long Drug (min) similarity between targeted binding pocket and tyrosine half-
Slide 21: Estimated Target Population for Irreversible Menin Inhibitor BMF-219
Estimated Target Population for Irreversible Menin Inhibitor BMF-219 Leukemia Lung Cancer Liquid Tumors Solid Tumors Est. US Patient Est. US Patient NPM-1 Pancreatic Population Population Disease Disease Leukemias (Annual (Annual Cancer Incidence) Incidence) Fusion Breast AML/ALL 2,500 EWS 1,000 (ML
Slide 22: Menin Pathway Validation – Type II Diabetes
Menin Pathway Validation – Type II Diabetes • Menin (MEN1) controls differentiation of pancreatic stem cells into adult, glucose-responsive Beta Cells • Expression of MEN1 and MEN1 target genes (p27) is significantly decreased with increasing Concentrations of Glucose • Glucose induces islet Beta-ce
Slide 23: Biomea Fusion Intellectual Property
Biomea Fusion Intellectual Property We believe our Patent Portfolio with novel irreversible Scaffolds is strong and growing We have a strong Intellectual Property Portfolio (IP) which is growing every month. Our IP consists of several pending US and ex-US patent applications and several trademarks r
Slide 24: Corporate Milestones
Corporate Milestones Developing BMF-219 for multiple indications and building out a platform of irreversible inhibitors 2021 and beyond ü 15 April 2021, IPO. Sale of 9.823 M shares at $17 per share, raising after fees $153M with a total share count of 29.5M. Total Cash at the end of Q1 was $57.5M, t
Slide 25: Thank You
Thank You 25Thank You 25